Figure 3.

Improved inhibition of ovarian carcinoma by NGR sequence‐modified endostatin (NGR‐endostatin). (A) Bolus injection: The mouse ovarian carcinoma cell line, LM3, was injected subcutaneously into female athymic mice. After tumor establishment, mice were randomized and treated either with endostatin or with NGR‐endostatin at a dose of 20 mg/kg per day. Treatment was continued for 12 days. Squares: phosphate‐buffered saline control; triangles: endostatin; circles: NGR‐endostatin. (B) Slow‐release administration: Inhibition of human ovarian carcinoma (MA148) growth in athymic nude mice by NGR‐endostatin encapsulated into alginate beads. Arrows represent treatment schedule. Squares: alginate bead control; triangles: endostatin; circles: NGR‐endostatin. The mean tumor volume of control and treated groups are shown. Statistical significance was determined with a Student t test. Error bars indicate the standard error.